Amgen Extended Dosing- AMG 509 20250211- A Phase 1b, Open-Label Study of Xaluritamig (AMG 509) in Adults With Metastatic Castration-Resistant Prostate Cancer
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
September 2, 2026
End Date
August 26, 2031
Awarded By
Amgen, Inc.
Start Date
September 2, 2026
End Date
August 26, 2031